A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

Trial Profile

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs AMP 514 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Amplimmune; MedImmune
  • Most Recent Events

    • 04 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 05 Apr 2017 Results of development and validation of population PK model of MEDI0680 (n=56) and sequential PK-PD analysis (n=35), presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 20 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top